[HTML] sciencedirect.com

[HTML][HTML] Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

JM Bauml, BT Li, V Velcheti, R Govindan… - Lung cancer, 2022 - Elsevier
Objectives Effective therapy for non–small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …
被引用次数：35 相关文章
[HTML] nih.gov

[HTML][HTML] Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

JM Bauml, BT Li, V Velcheti, R Govindan… - Lung cancer …, 2022 - ncbi.nlm.nih.gov
Objectives: Effective therapy for non–small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

JM Bauml, BT Li, V Velcheti, R Govindan… - 2022 - digitalcommons.wustl.edu
Objectives: Effective therapy for non–small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.

JM Bauml, BT Li, V Velcheti, R Govindan… - Lung Cancer …, 2021 - europepmc.org
Objectives Effective therapy for non-small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …
[PDF] kuleuven.be

[PDF][PDF] Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

JM Bauml, BT Li, V Velcheti, R Govindan… - lirias.kuleuven.be
Objectives: Effective therapy for non–small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

JM Bauml, BT Li, V Velcheti, R Govindan… - Lung …, 2022 - profiles.wustl.edu
Objectives: Effective therapy for non–small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

JM Bauml, BT Li, V Velcheti… - Lung cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Objectives Effective therapy for non-small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …
[PDF] core.ac.uk

[PDF][PDF] Please let us know how this document benefits you.

JM Bauml, BT Li, V Velcheti, R Govindan… - core.ac.uk
Objectives: Effective therapy for non–small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

JM Bauml, BT Li, V Velcheti, R Govindan… - Lung …, 2022 - lungcancerjournal.info
Objectives Effective therapy for non–small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

JM Bauml, BT Li, V Velcheti… - Lung …, 2022 - mdanderson.elsevierpure.com
Objectives: Effective therapy for non–small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …